D
ry eye disease (DED) is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film that results in symptoms of discomfort, pain, and visual disturbances that significantly affect quality of life. 1, 2 Tear film instability, hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities play etiological roles in DED. 2 It is prevalent and is one of the most common reasons that patients seek care from an ophthalmologist, 3 affecting up to 50% of adults. 4 There currently is no gold standard test for diagnosing DED, and as a result, a variety of diagnostic tests are used. Traditional tests include ocular surface staining with a variety of vital dyes, tear break-up time, and Schirmer testing. 5 In recent years, newer tests have become available including tear osmolarity testing, MMP-9 testing, and various methods to image the tear film and meibomian glands. 5, 6 However, it is unknown how the introduction of these new testing modalities has influenced the way ophthalmologists evaluate patients with DED.
In addition, a subset of patients with DED have underlying Sjogren syndrome (SS), a chronic, debilitating, and potentially deadly autoimmune disease, which is characterized by irreversible damage to the lacrimal glands and salivary glands with a loss of tear and saliva production, leading to a significant reduction in quality of life. [7] [8] [9] The disease is also associated with autoantibody production, systemic complications, and an almost 20-fold higher risk of lymphoma that increases with disease duration. 10 Lacrimal gland involvement in SS often leads to aqueous deficient dry eye, which is classically associated with a marked decrease in tear production and severe ocular surface inflammation. 11 Sjogren syndrome is estimated to affect between two and four million Americans, with half of the patients with SS remaining undiagnosed because of the nonspecific nature of early clinical manifestations and an average delay in diagnosis of up to 7 years from the onset of symptoms. [11] [12] [13] The diagnosis of SS is complex and requires collaboration among multiple subspecialists including ophthalmology, rheumatology, and oral medicine. Several different sets of classification criteria for SS have been proposed. One of the more commonly used classification criteria sets is the American-European Consensus Group (AECG) criteria. The AECG set of criteria includes both symptoms and signs of DED (Schirmer without anesthesia of #5 mm/5 min or vital dye staining of the ocular surface $4 van Bijsterveld scoring system). 8 In 2012, the American College of Rheumatology (ACR)/Sjogren's International Collaborative Clinical Alliance (SICCA) criteria were proposed that no longer included subjective symptoms and only included objective signs. 14 Finally, more recently, the ACR-European League Against Rheumatism (EULAR) criteria were proposed, which contains elements of both the AECG and ACR/SICCA criteria. 15 Because patients with SS often have DED, they frequently first seek care from an ophthalmologist, who is in a position to facilitate early referrals for workups for SS. However, it is unclear which symptoms and signs ophthalmologists currently use when deciding whether or not to refer a dry eye patient for a SS workup or how often dry eye patients are being referred for evaluations. Early diagnosis and management are essential for the optimal management of SS to improve quality of life and to monitor patients for the development of systemic complications such as lymphoma. 11 The diagnosis of SS is hampered by significant limitations of sensitivity and specificity of traditional autoantibodies with an established link to SS. 16, 17 Although Sjogren Syndrome A (SSA/Ro) and Sjogren Syndrome B (SSB/La) antibodies are traditionally described as the hallmark antibodies of SS and are included in the diagnostic criteria for SS, they are only found in 60% to 70% of SS patients presenting to rheumatology clinics. 18 Recently, new candidate SS antibodies were described in a mouse model for SS 19 and are commercially available in the "Sjo" finger stick kit performed in the office or as a blood draw (Bausch & Lomb, Rochester, NY). However, it is unclear how many ophthalmologists are currently aware of this kit and how many are using it in their practice or are ordering this blood test.
Currently, there is no standardized approach to patients with DED regarding ophthalmologic evaluation or referral of patients for an SS workup. Therefore, our goal was to survey ophthalmologists to assess current practice patterns regarding the evaluation of patients with DED and referrals for SS workups.
METHODS
In August 2015, we conducted an online survey of ophthalmologists using REDCap.com, a secure web application that can be used to build and manage online survey and databases. 20 The survey invitation was sent to 474 ophthalmologists from across the country who are or were affiliated with the Scheie Eye Institute or Wills Eye Hospital. The questionnaire created for this study was designed to assess each ophthalmologist's practice patterns regarding dry eye patients and referrals for evaluations for SS and has not previously been validated (see Table  1 , Supplemental Digital Content 1, http://links.lww.com/ICL/A69). Respondents ranked their top three choices from each list.
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The survey included questions regarding the ophthalmologists' specialties, practice setting, and dry eye patient populations. Ophthalmologists were also asked about their knowledge and preferences regarding dry eye testing in their offices, as well as about the use of standardized dry eye grading scales. The surveyed ophthalmologists were asked to rank their top three traditional dry eye tests from the following tests: fluorescein staining of the cornea, tear break-up time, lissamine green staining of the conjunctiva, rose bengal staining of the conjunctiva, and Schirmer test (unanesthetized or anesthetized). Similarly, they were asked to rank their top three newer dry eye tests from the following tests: tear osmolarity assessment, MMP-9 testing with InflammaDry (RPS Diagnostics, Sarasota, FL), LipiView (TearScience, Morrisville, NC), optical coherence tomography of tear film, and meibography. The survey also included questions regarding their general knowledge about SS, the Sjo test (Bausch & Lomb), as well as referral patterns and testing of dry eye patients with suspected SS.
Ophthalmologists were asked to respond the survey questions through the Redcap.com web application.
Statistical Analysis
We performed descriptive analyses of this survey data by calculating the percentage of respondents with a response in a particular category. We compared survey responses between ophthalmologists in academic practices versus nonacademic practices, and between cornea specialists versus noncornea specialists using the Fisher exact test. All the statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Of the 474 survey invitations sent out, 101 (21.3%) ophthalmologists responded and completed the survey. The characteristics of survey respondents are shown in Table 1 . The majority of the respondents were cornea specialists (42.6%), followed by comprehensive ophthalmologists (20.8%). More than half of the respondents were in full-time private practice (56.4%), with approximately one-third practicing full-time in an academic institution (35.6%). Overall, there were no statistically significant differences in the responses of physicians in academic versus nonacademic settings (all P.0.11). The majority (78.2%) of respondents had been in practice for more than 5 years. Overall, more than half (60.4%) of the participants reported that dry eye patients make up approximately 20% to 60% of their practice, and that they spent on average 5 min or less performing a dry eye examination in the office.
Dry Eye Tests
The results of the ranking of top three traditional dry eye tests and top three newer dry eye tests are shown in Table 2 . Most participants reported that they more frequently used traditional dry eye tests compared with newer tests in the office. The most common traditional dry eye tests performed were corneal fluorescein staining (ranked as most common by 62%), tear break-up time (49%), and anesthetized Schirmer's test (32%). Among the newer diagnostic tests, tear osmolarity assessment was the most frequently test used, with 18% ranking this as most commonly used newer test used.
Dry Eye Grading Scales
The majority of the respondents (82.2%) reported that they do not routinely use a standard DED severity grading scale. Approximately half of the respondents (51.5%) were familiar with the Dry Eye WorkShop (DEWS) dry eye severity grading scale 1 ; however, among those familiar with the scale, only 19% (n¼10) use it routinely in their offices. Most (57.1%) of those who do not routinely use the scale feel it takes too long to use in the office. Only a quarter of the respondents (25.7%) were familiar with the SICCA Ocular Staining Score (OSS) grading scale 21 and among those who were familiar, only about a quarter (23%, n¼6) use it routinely in their offices. Those who do not use the OSS grading routinely felt it either takes too long (42.1%) or is not clinically useful (47.4%). Table 3 summarizes the responses to questions about SS. Half of the respondents (50.5%) reported that they refer fewer than 5% of their dry eye patients for SS workups, with 18% reporting that they never refer any patients. The most common reasons for referrals included positive review of systems (60.4%) (most common extraocular symptom: dry mouth), severe dry eye symptoms (50.5%) or signs (46.5%), or dry eye that is refractory to treatment (41.6%). The most common ocular signs that would cause referral for SS workup were severe corneal staining (59.4%), unanesthetized Schirmer score of ,5 mm (37.6%). and severe conjunctival lissamine green staining (28.7%). Approximately two-thirds (67%) of the respondents were not familiar with either one of the two current sets of classification criteria for SS available at the time of the survey, specifically the AECG 8 and the ACR/SICCA. 14 Over half of the respondents (53.5%) had never heard of the Sjo test. Of those who were familiar with it, only 7% of ophthalmologists were routinely checking this test on their dry eye patients. Ninety-three percent of respondents were unsure how the Sjo test results would guide their management of patients. The overwhelming majority of respondents (83%) felt that there was a need for an evidence-based standardized screening tool for dry eye patients to decide who should be referred for evaluation for SS.
Sjogren Syndrome
When comparing referral patterns for SS workups and between cornea and noncornea specialists (Table 4) , cornea specialists reported referring patients more often to a rheumatologist (100% vs. 66.7% for referring at least 5%, P,0.0001, Fisher exact test) or ordering blood-work for SS antibodies (79.1% vs. 40.7% for ordering at least 5%, P,0.0001, Fisher exact test) compared with noncornea specialists. Cornea specialists were also more commonly familiar with the DEWS dry eye severity grading scale than noncornea specialists (43.9% vs. 17.0%, P¼0.006, Fisher exact test).
DISCUSSION
Our study survey provides insight into how ophthalmologists currently approach patients with DED. Our results can be compared with a survey conducted in 2000 by Korb 22 in which he surveyed 36 optometrists and 41 ophthalmologists nationally and internationally with a background in dry eye about their preferred test. In contrast to that study, our survey included 101 ophthalmologists in the United States who are comprehensive ophthalmologists and subspecialists. Similar to the study conducted by Korb 22 15 years ago, we found that ophthalmologists in our survey still prefer using traditional dry eye tests despite the increased availability of newer in-office DED tests. However, in contrast to Korb's study in which there was no clear top choice of DED test, our study found that more than half of the ophthalmologists reported that corneal staining with fluorescein as the most common test for the evaluation of patients with DED. Also consistent with previous reports, conjunctival staining with lissamine green is not frequently used in DED evaluations, despite the fact that conjunctival staining with lissamine green is an integral part of the DEWS severity grading scale and the OSS scale that is part of the ocular classification criteria for SS. Therefore, it is critical that ophthalmologists perform conjunctival staining with lissamine green, in addition to corneal staining with fluorescein.
Lissamine green staining of the conjunctiva is included in both the DEWS severity scale and OSS scale. Dry eye severity scales help stratify and categorize patients' dry eye disease, and can be useful in monitoring treatment response. However, our study found a low level of familiarity with the use of these grading scales, and most of our respondents felt that these scales either took too long or were not clinically useful. Our study found that only a quarter of the respondents were familiar with the SICCA OSS grading scale 21 and among those who were familiar, only about a quarter (23%, n¼6) use it routinely in their offices. The OSS scale was proposed by the SICCA group to develop a standardized method for evaluating for ocular involvement in SS 21 and is a part of the ACR/ SICCA criteria and also the more recently approved ACR/EULAR classification criteria for SS. 15 The OSS scale is composed of scores from corneal staining with fluorescein as well as conjunctival staining with lissamine green. The OSS score is calculated by the summation of the fluorescein score for the cornea and the lissamine green scores for the nasal and temporal bulbar conjunctiva; with additional points given for the presence of central corneal staining, confluence, or the presence of filaments. 21 Therefore, to assess patients for the ocular classification criteria for SS, the ocular surface must be assessed using the OSS grading scale. Increased awareness and utilization of the OSS grading scale is needed so that dry eye patients can be properly evaluated for possible SS.
In our study, we found that the most common reasons for SS referrals included positive review of systems (most common extraocular symptom: dry mouth) and the presence of severe corneal staining. Overall, there was a low referral rate of dry eye patients for SS evaluations, with half of the respondents reporting that they refer less than 5% of their dry eye patients for SS workups, and about 1 in 5 reporting that they never refer any patients. There seems to be several contributing factors to this low referral rate. Approximately two-thirds of respondents were not familiar with either one of the two current sets of classification criteria for SS available at the time of the survey. We found that most ophthalmologists in our survey felt that there is a need for a standardized approach to dry eye evaluation and tools for screening those who warrant referral for SS workups. An increased awareness and familiarity with the SS classification criteria and the OSS grading scale as well as the development of a standardized screening tool could increase referrals of dry eye patients for SS evaluations.
More than half of the respondents had never heard of the Sjo test, and of those who were familiar with the test, the majority were unsure how the results affect their management. Further studies regarding the interpretation and clinical meaning of the Sjo test results would be helpful and may increase use of this test by ophthalmologists.
Finally, we found that many ophthalmologists have been slow to adopt newer dry eye tests into practice and most continue to rely on traditional in-office dry eye examinations. Newer diagnostic modalities in dry eye, such as tear osmolarity assessment, determination of surface inflammatory markers (e.g., matrix metalloproteinase 9) by using in-office rapid screening kits, LipiView, and meibography, are available adjunctive tests for the evaluation of DED. It is possible that the hesitation to implement these tests in the office is due to the lack of evidence that show an additional benefit to the evaluation of patients with DED over traditional tests. 23 Our study had certain limitations. For example, our survey did not include questions about all possible biomarkers for SS such as HLA-DR or cytokines. However, because the Sjo kit is currently available and marketed to ophthalmologists, we chose to focus on assessing knowledge about those antibody tests. Future surveys that include other SS biomarkers would be helpful. In addition, our sample size was limited in that 101 ophthalmologists responded to the survey. However, this response rate is similar or higher than that of other previously published survey studies, 24, 25 and a strength of our study was that it included cornea specialists as well as noncornea specialists. Finally, our study was only sent to ophthalmologists and did not include other eye care providers such as optometrists. In the future, we plan to survey a broader range of eye care providers to increase the generalizability of our findings.
CONCLUSIONS
Despite the introduction of several new diagnostic dry eye tests in recent years, we found that ophthalmologists continue to prefer the use of traditional dry eye tests in practice, with the most common test being corneal fluorescein staining. There continues to be an underreferral of dry eye patients for SS workups, which is contributing to the continued underdiagnosis of the disease. This underreferral could partly be due to a lack of familiarity with the OSS grading scale used to evaluate patients for the ocular criteria for SS. The overwhelming majority of ophthalmologists in our study felt that there is a need for an evidence-based standardized screening tool for dry eye patients to decide who should be referred for SS evaluation. An increased knowledge of the SS classification criteria and the development of improved standardized screening tools could help in the optimization of timely evaluations for SS, leading to earlier diagnosis and better outcomes.
